to establish animal models for COVID-19 infection, to define the pathogenesis and immunology of infection, and to utilize these models to test vaccines and/or therapeutics

Grant number: INV-006131

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2020
  • Known Financial Commitments (USD)

    $4,352,365
  • Funder

    Gates Foundation
  • Principal Investigator

    N/A

  • Research Location

    United States of America
  • Lead Research Institution

    Beth Israel Deaconess Medical Center Inc.
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

N/A

Publicationslinked via Europe PMC

Ad26.COV2.S prevents upregulation of SARS-CoV-2 induced pathways of inflammation and thrombosis in hamsters and rhesus macaques.

Scalable, methanol-free manufacturing of the SARS-CoV-2 receptor-binding domain in engineered Komagataella phaffii.

Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice.

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.

SARS-CoV-2 infection protects against rechallenge in rhesus macaques.